-
Tytuł:
-
Association of mammography and ultrasound features with MammaPrint in patients with estrogen receptor-positive, HER2-negative, node-positive invasive breast cancer.
-
Autorzy:
-
Choi WJ; Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, 65526Asan Medical Center, Seoul, Republic of Korea.
Sim H; Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, 65526Asan Medical Center, Seoul, Republic of Korea.
Kim HJ; Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, 65526Asan Medical Center, Seoul, Republic of Korea.
Cha JH; Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, 65526Asan Medical Center, Seoul, Republic of Korea.
Shin HJ; Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, 65526Asan Medical Center, Seoul, Republic of Korea.
Chae EY; Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, 65526Asan Medical Center, Seoul, Republic of Korea.
Kim HH; Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, 65526Asan Medical Center, Seoul, Republic of Korea.
-
Źródło:
-
Acta radiologica (Stockholm, Sweden : 1987) [Acta Radiol] 2021 Dec; Vol. 62 (12), pp. 1592-1600. Date of Electronic Publication: 2020 Dec 10.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Dec. 2012- : London : Sage
Original Publication: Stockholm, Sweden : Acta Radiologica, [1987-
-
MeSH Terms:
-
Neoplasm Recurrence, Local*
Receptor, ErbB-2*
Receptors, Estrogen*
Breast Neoplasms/*chemistry
Breast Neoplasms/*diagnostic imaging
Mammography/*methods
Ultrasonography, Mammary/*methods
Adult ; Age Factors ; Aged ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Epidemiologic Factors ; Female ; Humans ; Lymph Nodes/pathology ; Microarray Analysis ; Middle Aged ; Neoplasm Grading ; Neoplasm Invasiveness
-
Contributed Indexing:
-
Keywords: Breast cancer; MammaPrint; mammography; ultrasound
-
Substance Nomenclature:
-
0 (Receptors, Estrogen)
EC 2.7.10.1 (Receptor, ErbB-2)
-
Entry Date(s):
-
Date Created: 20201211 Date Completed: 20211209 Latest Revision: 20211214
-
Update Code:
-
20240104
-
DOI:
-
10.1177/0284185120980003
-
PMID:
-
33302692
-
Background: MammaPrint is a 70-gene signature microarray assay that predicts the likelihood of recurrence of breast cancer and chemotherapeutic benefits.
Purpose: To investigate the association between mammography and ultrasound (US) features and MammaPrint results in patients with estrogen receptor (ER)-positive, HER2-negative, node-positive invasive breast cancer, and to identify the predictive factors for high risk of recurrence.
Material and Methods: This retrospective study included 251 patients with ER-positive, HER2-negative, 1-3 node-positive invasive breast cancer. Mammography and US findings were reviewed according to the BI-RADS criteria. The association between MammaPrint results and the clinicopathological and imaging features was evaluated. Logistic regression analysis was performed to identify independent predictors for high risk of recurrence.
Results: Of the patients, 143 (57.0%) and 108 (43.0%) had low and high risks for recurrence on MammaPrint, respectively. Young age (odds ratio [OR] 1.08; 95% confidence interval (CI) 1.04-1.12; P <0.001), posterior enhancement on US (OR 2.45; 95% CI 1.16-5.20; P = 0.019), absence of posterior shadowing on US (OR 3.19; 95% CI 1.17-8.62; P = 0.023), high histologic grade (OR 113.36; 95% CI 6.79-1893.53; P = 0.001), and high Ki-67 level (OR 4.90; 95% CI 2.62-9.17; P <0.001) were independently associated with high risk of recurrence on multivariate logistic regression analysis.
Conclusion: Posterior features in US may predict a high risk of recurrence in patients with ER-positive, HER2-negative, node-positive invasive breast cancer, which may be useful in enhancing the diagnostic value of MammaPrint and aid in the decision-making process regarding treatment.
